SCHEMBL23218869

SCHEMBL23218869

COC(=O)Cc1cccc(C#N)c1OCc1coc2ccc(Br)cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.38
MAOA P21397 2/20 0.38
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
PSMB8 P28062 1/20 0.36
PSMB5 P28074 1/20 0.36
MAPT P10636 4/20 0.35
KDM4E B2RXH2 3/20 0.35
TP53 P04637 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
HSD17B10 Q99714 1/20 0.35
KCNH2 Q12809 1/20 0.34
MTNR1A P48039 3/20 0.34
MTNR1B P49286 2/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852883 1.00 MAOB (0.38) MAOBMAOAALDH1A1HTTPSMB8
SCHEMBL23218940 0.91 KCNH2 (0.35) MAOBMAOAALDH1A1HTTPSMB8
SCHEMBL29852664 0.91 KCNH2 (0.35) MAOBMAOAALDH1A1HTTPSMB8
SCHEMBL29852699 0.84 MAOA (0.40) MAOBMAOAALDH1A1HTTMAPT
SCHEMBL23219080 0.84 MAOA (0.40) MAOBMAOAALDH1A1HTTMAPT
SCHEMBL28736109 0.83 CFD (0.44) PSMB8PSMB5MAPTTP53KMT2A
SCHEMBL29853127 0.83 CFD (0.44) PSMB8PSMB5MAPTTP53KMT2A
SCHEMBL23218680 0.78 THRB (0.41) MAOBMAOAALDH1A1HTTMAPT
SCHEMBL29853258 0.78 THRB (0.41) MAOBMAOAALDH1A1HTTMAPT
SCHEMBL23218697 0.77 MAPT (0.40) MAOBMAOAALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MAOB 1035/4885MAOA 1416/4885ALDH1A1 2667/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MAOB 453/4885MAOA 795/4885ALDH1A1 3142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.